Everest Clinical Research (Arlington) Acquires August Research

Arlington Capital Partners Makes Majority Investment in Everest Clinical Research Corporation

December 7, 2020

Healthcare Services

Washington, D.C.-based private equity firm Arlington Capital Partners has made a majority investment in Toronto-headquartered Everest Clinical Research Corporation, with Everest's founding shareholders and senior management rolling equity and continuing to lead the company. Everest is a full-service contract research organization (CRO) with ~300 employees across Toronto, Little Falls (NJ) and Shanghai; Arlington will support expansion of service lines, capabilities and headcount to drive growth.

Everest Clinical Research Acquires Brightech International

December 2, 2022

Healthcare Services

Everest Clinical Research, a PE-backed full-service contract research organization, has acquired Brightech International, a specialist CRO focused on biostatistics, statistical programming, and clinical data management. The deal strengthens Everest's biometrics capabilities and global footprint, complementing its therapeutic strengths in Oncology, CNS, and Immunology.

Evestia Clinical Merges with Atlantic Research Group

July 15, 2025

Healthcare Services

Kester Capital-backed Evestia Clinical has merged with US-based Atlantic Research Group (ARG) to create a larger independent specialist CRO with dual headquarters in Letchworth, UK and Charlottesville, VA. The combination expands Evestia's US footprint and adds neurology and late-stage clinical trial capabilities while broadening therapeutic expertise across oncology, rare diseases, immunology and inflammation.

Catalyst Clinical Research Acquires Aptus Clinical

May 4, 2022

Healthcare Services

Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.

ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader

December 10, 2020

Healthcare Services

ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.

Astorg Joins Nordic Capital and Novo Holdings in Recapitalization of ERT

October 21, 2019

Healthcare Services

Astorg will invest in eResearchTechnology, Inc. (ERT), joining existing owners Nordic Capital, Novo Holdings A/S and the ERT management team in a broadened ownership group. The investors will support continued development of ERT's clinical trial technology platform, expand operational capabilities, and pursue selective add-on acquisitions to drive future growth; financial terms were not disclosed.